Shanghai CP Guojian Pharmaceutical Co Ltd
This is a biopharmaceutical company established in 2002 under the China International Trust and Investment Corp working in R&D, scale development, industrialization and the commercialization of antibody drugs. It has grown into a leader in China in the antibody sector providing targeted drugs for cancer, autoimmune diseases and organ transplantation immunosuppressant treatments and has a wholly owned subsidiary, the Shanghai CPGJ pharmaceutical development Co.
CP Guojian has a leading team of professionals developing its core technologies new biological therapies with an outstanding capacity for R&D, clinical work, production and commercialization.
It has strict quality standards and sound management and one of its leading products, Etanercept, had successful results in 2005 as the first officially approved antibody fusion protein drug in China, with wide applications in China and abroad. The company is a leader in production in China's bio-medicine industry and it has China’s largest antibody drug production lines, and international-standard facilities and equipment.
It has a Contract Manufacture Organization platform to provide one-stop service for global pharmaceutical clients, and overall production and operation solutions.